XERS Xeris Biopharma Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why XERS matters now
Xeris Biopharma Holdings, Inc. (XERS) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.34 with -3.25% on the session and $1.44B in market capitalization; recent performance reads 1-month +17.40% and YTD -11.46%.
The latest financial table shown here is Q1 2026, with revenue of $83.1M, net income of $2.2M, and EPS of $0.01. Investors can compare that operating picture with valuation signals such as P/E 1827.02 and FCF yield 3.9%.
The latest indexable market news headline is "Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.60; recent insider activity includes Brady James Aloysius filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
1827.02
PEG
18.09
P/B
91.09
P/S
3.81
EV/EBITDA
24.40
DCF Value
$-66.87
FCF Yield
3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.6%
Operating Margin
11.4%
Net Margin
3.8%
ROE
735.0%
ROA
3.1%
ROIC
12.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $83.1M | $2.2M | $0.01 |
| Q4 2025 | $85.8M | $11.1M | $0.06 |
| FY 2025 | $291.8M | $554.0K | $0.00 |
| Q3 2025 | $74.4M | $621.0K | $0.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.82
Target (Median)
$6.60
Target Range
$4.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.90
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.